ESMO 2023 | Lesion responses to lenvatinib and pembrolizumab based on organ sites

Viktor Grünwald, MD, PhD, University Hospital Essen, Essen Germany, discusses the findings of a post-hoc analysis subsequent to the Phase III CLEAR (NCT02811861) trial measuring lesion responses to lenvatinib and pembrolizumab, categorized into organ site, to treat advanced renal cell carcinoma. In the CLEAR trial, lenvatinib plus pembrolizumab demonstrated superior tumor response, regardless of baseline metastatic characteristics. This post hoc analysis examined response rates in lenvatinib plus pembrolizumab (n=355) vs. S (n=357) arms, considering factors like the site of metastasis, the number of metastatic sites, and the size of target lesions. Results showed that lenvatinib plus pembrolizumab had a better objective response rate (ORR) and progression-free survival (PFS) in all subgroups, especially in patients with a higher disease burden. These findings support lenvatinib plus pembrolizumab as the standard of care for first-line RCC treatment.This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.